DIOS-CoVax - A vaccine designed to protect against COVID-19 and future Coronavirus epidemics, mitigating antibody enhanced disease.

DIOS-CoVax - 一种疫苗，旨在预防 COVID-19 和未来的冠状病毒流行，减轻抗体增强疾病。

• 批准号: 72845
• 金额: $ 246.37万
• 依托单位: DIOSYNVAX LTD.
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=72845
• 关键词: DIOS; CoVax; vaccine; designed; protect

Safe and highly effective vaccines are the most promising medical interventions for the prevention of infectious diseases. At the time of writing, there have been over 5 million cases and 330,000 deaths reported to the WHO. The coronavirus, referred to as SARS-CoV-2, causes a respiratory disease termed COVID-19\.Current experimental Spike-based coronavirus vaccines have limited efficacy in animals tested with the experimental vaccine, and there remains concerns about longer-term immunopathology. Animals given experimental SARS vaccines suffered more serious lung disease when challenged with coronavirus than unvaccinated animals who were infected with coronavirus, meaning human trials and vaccine development were impossible.Our study uses innovative technologies to avoid these problems by selecting modified coronavirus antigens that will be incorporated in the vaccine and will trigger the human immune system to produce the important and focussed antibody responses that we need to protect us against the virus. This proposal will take this new vaccine through the manufacturing and safety testing phases to a completed first in human phase 1 trial. Of note, the DNA vaccine does not require a cold-chain and can be administered without a needle, relatively pain-free, allowing highly efficient mass vaccination strategies to be rapidly deployed.

安全高效的疫苗是预防传染病最有希望的医疗干预措施。在撰写本报告时，已向世界卫生组织报告了500多万个病例和33万人死亡。这种冠状病毒被称为SARS-CoV-2，会导致一种名为新冠肺炎的呼吸道疾病。目前基于钉状病毒的实验性冠状病毒疫苗对实验疫苗测试的动物效果有限，长期免疫病理学仍令人担忧。接受实验性SARS疫苗的动物在受到冠状病毒攻击时会比未接种冠状病毒的动物患上更严重的肺部疾病，这意味着人类试验和疫苗开发是不可能的。我们的研究使用创新技术来避免这些问题，方法是选择修改后的冠状病毒抗原，这些抗原将被整合到疫苗中，并将触发人类免疫系统产生重要的和集中的抗体反应，这是我们保护我们免受病毒攻击所需的。这项提案将使这种新疫苗通过制造和安全测试阶段，进入完成的人类第一阶段试验。值得注意的是，DNA疫苗不需要冷链，可以不用针头注射，相对无痛，允许快速部署高效的大规模疫苗接种战略。